INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - On July 9, 2025, Ultragenyx and Mereo BioPharma Group announced the progress of the Phase 3 Orbit study for UX143 (setrusumab) in patients with osteogenesis imperfecta, with a final analysis expected by the end of the year [3] - Following the announcement, Ultragenyx's stock price dropped by $10.41, or 25.11%, closing at $31.04 per share on July 10, 2025 [3] Group 2 - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having pioneered the field of securities class actions over 80 years ago [4] - The firm has a history of recovering multimillion-dollar damages awards for victims of securities fraud and corporate misconduct [4]